Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01793103 · ClinicalTrials.gov registry record

Brigham and Women's Rheumatoid Arthritis Sequential Study

A clinical trial of Rheumatoid Arthritis, sponsored by Brigham and Women's Hospital.

Active
Registry status
1,598
Enrollment target
1
Study location

NCT01793103 is a study of Rheumatoid Arthritis that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 1,598 participants, below the 4,683-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01793103, a study of Rheumatoid Arthritis, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.

ACTIVE NOT RECRUITING
Registry status
1,598 participants
Enrollment target
1
Study location

Study Summary

The goal of the present study is to establish a prospective observational cohort of Rheumatoid Arthritis patients in order to 1. Determine and validate biomarkers that predict drug response and toxicity in RA. 2. Determine and validate biomarkers that predict disease activity and prognosis in RA. 3. Evaluate the natural history of treated RA in terms of its clinical, functional and economic outcomes.

Conditions Studied

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 1,598 participants
Start Date 2003-03
Est. Completion 2028-03

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT01793103

The ClinicalTrials.gov registry entry for NCT01793103 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,598 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,683-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (66% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 0 interventions.

NCT01793103 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01793103 about?

NCT01793103 is a clinical study titled "Brigham and Women's Rheumatoid Arthritis Sequential Study". The goal of the present study is to establish a prospective observational cohort of Rheumatoid Arthritis patients in order to 1. Determine and validate biomarkers that predict drug response and toxicity in RA. 2. Determine and validate biomarkers that predict disease activity and prognosis in RA. 3...

What is the current status of trial NCT01793103?

This trial is currently active not recruiting. The enrollment target is 1,598 participants. The study started on 2003-03. Estimated completion is 2028-03.

What conditions does trial NCT01793103 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

Who is sponsoring clinical trial NCT01793103?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01793103 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.